Behavioral Intervention
Collaborative Care for Substance Use and Mental Health Disorders
This trial will help researchers understand if working with a peer-case manager helps people with HIV who also have substance use or mental health disorders better access and engage in care for those disorders.
Antiretroviral Therapy
Biktarvy After Kidney Transplant for HIV
This trial will test a new HIV drug, Biktarvy, to see if it is safe and effective. People with HIV who have had a kidney transplant will be switched from their current medication to Biktarvy. The trial will last 48 weeks.
Behavioral Intervention
PrEP Adherence Intervention for HIV Prevention
This trial will assess if using video directly observed therapy with real-time contingency management (VDOT-CM) may help people assigned male sex at birth who have sex with men (MSM) who inject methamphetamine adhere to PrEP.
Behavioral Intervention
Wellness Intervention for Smoking Cessation in Veterans with HIV
This trial will compare an HIV-specific wellness intervention to standard care (referral to national VA Quitline and SmokefreeVET texting program) to see which is more effective.
Popular Filters
Trials for Human Immunodeficiency Virus Infection Patients
Integrase Inhibitor
Long-acting Cabotegravir + Rilpivirine for HIV
This trial is designed to compare the antiviral activity and safety of two regimens of an injectable combination of cabotegravir and rilpivirine given every 8 weeks or every 4 weeks, in adults living with HIV who are currently on a stable antiretroviral regimen.
Trials for HIV Patients
Integrase Inhibitor
Long-acting Cabotegravir + Rilpivirine for HIV
This trial is designed to compare the antiviral activity and safety of two regimens of an injectable combination of cabotegravir and rilpivirine given every 8 weeks or every 4 weeks, in adults living with HIV who are currently on a stable antiretroviral regimen.
Phase 3 Trials
Integrase Inhibitor
Long-acting Cabotegravir + Rilpivirine for HIV
This trial is designed to compare the antiviral activity and safety of two regimens of an injectable combination of cabotegravir and rilpivirine given every 8 weeks or every 4 weeks, in adults living with HIV who are currently on a stable antiretroviral regimen.
Trials With No Placebo
Integrase Inhibitor
Long-acting Cabotegravir + Rilpivirine for HIV
This trial is designed to compare the antiviral activity and safety of two regimens of an injectable combination of cabotegravir and rilpivirine given every 8 weeks or every 4 weeks, in adults living with HIV who are currently on a stable antiretroviral regimen.
Antiretroviral
E/C/F/TAF for HIV-1 Infection
This trial tests a single pill combining four HIV medications in adolescents and children. It aims to find the right dose and ensure safety for those new to treatment and those already on it. The pill works by stopping the virus from growing and spreading.
Trials Offering Remuneration
Virus Therapy
CH505 TF chTrimer Vaccine for HIV Prevention
This trial tests a new vaccine called CH505 TF chTrimer in healthy adults. The vaccine is combined with substances to see if it helps the immune system produce strong antibodies. The goal is to ensure the vaccine is safe and effective.
Antiretroviral Agent
Long-Acting Cabotegravir + rHuPH20 for HIV Infection
This trial is testing a long-lasting HIV medication called Cabotegravir, given as an injection. It also tests if adding rHuPH20 helps the medication spread better in the body. The study focuses on people who need long-term HIV treatment. Cabotegravir is the first long-acting injectable treatment option approved for adults with HIV-1.
Integrase Inhibitor
Long-acting Cabotegravir Formulations in Healthy Adults
This trial will assess the safety and effectiveness of two different cabotegravir formulations in healthy adults. Data from the first formulation will determine if the second one is assessed.
View More Related Trials
Frequently Asked Questions
Introduction to hiv infection
What are the top hospitals conducting hiv infection research?
In the ongoing battle against HIV infection, several hospitals have emerged as leading pioneers in clinical trials. One such institution is the GSK Investigational Site located in Austin, where researchers are actively conducting six trials to find innovative solutions for this persistent disease. With a remarkable tally of 55 completed trials dedicated to HIV infection, their commitment dates back to their first recorded trial in 2004. Similarly, their sister site in Los Angeles has also made significant strides with six active trials and an impressive history of 54 previous studies since initiating research on HIV infection back in 2002.
Not far behind are two other GSK Investigational Sites, one situated in Washington and another based out of New york City. Both locations boast six active HIV infection trials and have conducted extensive investigations into this challenging condition, with respective records of 45 and 36 completed studies ranging from treatments to prevention methods since their inaugural HIV trial date in 2002.
Additionally contributing to these efforts is the GSK Investigational Site located in Dallas. This Texas-based hospital is currently running six active clinical trials focused on combatting HIV infection while having accomplished an equally noteworthy total of 54 previously held studies since commencing its pioneering work back in the year 2002.
These institutions stand as beacons of hope amidst the ongoing fight against HIV/AIDS. By tirelessly pushing boundaries through rigorous clinical research, they strive toward breakthroughs that can potentially transform lives worldwide. The collective dedication displayed by these top hospitals underscores both the urgency and unwavering commitment required when tackling global health challenges.
Which are the best cities for hiv infection clinical trials?
When it comes to HIV infection clinical trials, several cities emerge as key hubs for research and advancement. New york, with its 46 active trials, focuses on treatments like Arm A and Standard of Care (SOC) Oral ART. Los Angeles follows closely behind with 34 ongoing studies investigating Treatment options and Cohort I. San Francisco and Chicago both boast 31 active trials, exploring various treatment strategies in different cohorts. Boston rounds out the list with 25 active trials delving into innovative approaches such as BG505 MD39.3 gp151 CD4KO mRNA. These cities serve as vital centers for individuals seeking participation in HIV clinical trials, offering hope for improved outcomes through cutting-edge research initiatives.
Which are the top treatments for hiv infection being explored in clinical trials?
The pursuit of effective treatments for HIV infection remains a priority in clinical trials. At the forefront is Intervention, currently being evaluated in one active trial dedicated to combating HIV infection. Since its introduction in 2009, this treatment has been part of five all-time trials aimed at addressing this persistent health challenge. Another promising contender is BG505 MD39.3 gp151 CD4KO mRNA, with one active trial and the distinction of being first listed just last year (2022) among all hiv infection trials. As researchers continue their tireless efforts, these potential treatments offer hope for improved outcomes and enhanced quality of life for individuals living with HIV infections worldwide.
What are the most recent clinical trials for hiv infection?
Exciting advancements are being made in the field of HIV infection, with recent clinical trials exploring new possibilities for treatment. One notable trial focuses on VH4004280, a potential therapeutic option that has entered Phase 2. Another study investigates the effectiveness of Cabotegravir Formulation F in participants during Phase 1. Additionally, VH3810109 Plus Cabotegravir is being evaluated during Phase 2 to determine its impact on HIV infection. Lastly, there is an ongoing Phase 4 trial assessing the efficacy and safety of Prep as a preventive measure against HIV transmission. These trials offer hope for improved outcomes and provide a glimpse into the future of HIV management strategies.
What hiv infection clinical trials were recently completed?
In recent years, numerous clinical trials have been completed to advance our understanding and treatment options for HIV infection. Some notable trials include a study sponsored by Janssen Research & Development, LLC, which investigated the effectiveness of DRV/COBI FDC and concluded in August 2022. ViiV Healthcare also conducted two trials: one evaluating VH4011499 (completed in May 2022) and another examining VH3810109 (completed in February 2022). Additionally, the National Institute of Allergy and Infectious Diseases (NIAID) concluded a trial on VRC07-523LS (20mg/kg, IV) in November 2021. These significant developments demonstrate ongoing efforts to combat HIV infection through innovative research initiatives.